Lead program NeoVAC
Immunetune’s lead program NeoVAC is a personalized neoantigen DNA vaccine harboring more than 20 neoantigens to elicit a powerful tumor-specific immune response. It has obtained preclinical Proof of Concept in cancer models including the combination with checkpoint inhibitors, which has been published in the journal Oncoimmunology in 2019. NeoVAC further incorporates the novel proprietary adjuvant PyroVant, which is specifically covered in a publication in the journal Vaccine in 2022.
The company has received scientific advice from the Paul-Ehrlich-Institute in Germany on the preclinical and clinical development plan, and has completed GLP toxicity studies early 2022.